CN1763021A - Method for purifying orlistat - Google Patents
Method for purifying orlistat Download PDFInfo
- Publication number
- CN1763021A CN1763021A CN 200510094601 CN200510094601A CN1763021A CN 1763021 A CN1763021 A CN 1763021A CN 200510094601 CN200510094601 CN 200510094601 CN 200510094601 A CN200510094601 A CN 200510094601A CN 1763021 A CN1763021 A CN 1763021A
- Authority
- CN
- China
- Prior art keywords
- orlistat
- solvent
- sample
- purifying
- crystallization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 title claims abstract description 70
- 229960001243 orlistat Drugs 0.000 title claims abstract description 70
- 238000000034 method Methods 0.000 title claims abstract description 28
- 238000002425 crystallisation Methods 0.000 claims abstract description 29
- 230000008025 crystallization Effects 0.000 claims abstract description 28
- 239000002904 solvent Substances 0.000 claims abstract description 24
- 239000012454 non-polar solvent Substances 0.000 claims abstract description 12
- 238000001953 recrystallisation Methods 0.000 claims abstract description 4
- 238000001914 filtration Methods 0.000 claims abstract description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical group CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 32
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 4
- 239000012535 impurity Substances 0.000 abstract description 18
- 238000000746 purification Methods 0.000 abstract description 13
- 238000009776 industrial production Methods 0.000 abstract description 2
- SIKWOTFNWURSAY-UHFFFAOYSA-N Lipstatin Natural products CCCCCCC1C(CC(CC=CCC=CCCCCC)C(=O)OC(CC(C)C)NC=O)OC1=O SIKWOTFNWURSAY-UHFFFAOYSA-N 0.000 description 13
- OQMAKWGYQLJJIA-CUOOPAIESA-N lipstatin Chemical compound CCCCCC[C@H]1[C@H](C[C@H](C\C=C/C\C=C/CCCCC)OC(=O)[C@H](CC(C)C)NC=O)OC1=O OQMAKWGYQLJJIA-CUOOPAIESA-N 0.000 description 13
- 239000000356 contaminant Substances 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 238000005984 hydrogenation reaction Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 238000000855 fermentation Methods 0.000 description 7
- 230000004151 fermentation Effects 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000000605 extraction Methods 0.000 description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 150000002613 leucine derivatives Chemical class 0.000 description 1
- 229960004232 linoleic acid Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005100946014A CN1763021B (en) | 2005-09-29 | 2005-09-29 | Method for purifying orlistat |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005100946014A CN1763021B (en) | 2005-09-29 | 2005-09-29 | Method for purifying orlistat |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1763021A true CN1763021A (en) | 2006-04-26 |
CN1763021B CN1763021B (en) | 2010-08-11 |
Family
ID=36747369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005100946014A Active CN1763021B (en) | 2005-09-29 | 2005-09-29 | Method for purifying orlistat |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1763021B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102070567A (en) * | 2011-01-21 | 2011-05-25 | 天津市海德安科医药科技发展有限公司 | Method for preparing high-purity orlistat by using reverse phase high-performance liquid chromatogram |
CN102070568A (en) * | 2011-02-28 | 2011-05-25 | 珠海联邦制药股份有限公司 | Preparation method of orlistat |
CN102558103A (en) * | 2010-12-13 | 2012-07-11 | 山东新时代药业有限公司 | Method for separating and purifying Orlistat |
CN102993135A (en) * | 2012-12-31 | 2013-03-27 | 山东新时代药业有限公司 | Method for purifying orlistat |
CN103739572A (en) * | 2014-01-09 | 2014-04-23 | 山东新时代药业有限公司 | Process for recovering orlistat crystallization mother solution |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1028115T3 (en) * | 1999-01-29 | 2003-03-17 | Hoffmann La Roche | Purification of lipstatin |
EP1470116A4 (en) * | 2001-12-04 | 2005-04-06 | Biogal Gyogyszergyar | Preparation of orlistat and orlistat crystalline forms |
WO2005007639A1 (en) * | 2003-07-17 | 2005-01-27 | Biocon Limited | Preparation of tetrahydrolipstatin by hydrogenation of lipstatin, solvent extraction and purification |
ES2329474T3 (en) * | 2003-09-12 | 2009-11-26 | Ranbaxy Laboratories Limited | PROCESS FOR THE PREPARATION OF ORLISTAT CRYSTAL FORMS. |
-
2005
- 2005-09-29 CN CN2005100946014A patent/CN1763021B/en active Active
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102558103A (en) * | 2010-12-13 | 2012-07-11 | 山东新时代药业有限公司 | Method for separating and purifying Orlistat |
CN102558103B (en) * | 2010-12-13 | 2015-01-14 | 山东新时代药业有限公司 | Method for separating and purifying Orlistat |
CN102070567A (en) * | 2011-01-21 | 2011-05-25 | 天津市海德安科医药科技发展有限公司 | Method for preparing high-purity orlistat by using reverse phase high-performance liquid chromatogram |
CN102070568A (en) * | 2011-02-28 | 2011-05-25 | 珠海联邦制药股份有限公司 | Preparation method of orlistat |
WO2012116520A1 (en) * | 2011-02-28 | 2012-09-07 | 珠海联邦制药股份有限公司 | Method for preparing orlistat |
CN102070568B (en) * | 2011-02-28 | 2012-09-26 | 珠海联邦制药股份有限公司 | Preparation method of orlistat |
CN102993135A (en) * | 2012-12-31 | 2013-03-27 | 山东新时代药业有限公司 | Method for purifying orlistat |
CN102993135B (en) * | 2012-12-31 | 2015-09-09 | 山东新时代药业有限公司 | A kind of purification process of orlistat |
CN103739572A (en) * | 2014-01-09 | 2014-04-23 | 山东新时代药业有限公司 | Process for recovering orlistat crystallization mother solution |
CN103739572B (en) * | 2014-01-09 | 2016-01-27 | 山东新时代药业有限公司 | A kind of orlistat crystalline mother solution recovery process |
Also Published As
Publication number | Publication date |
---|---|
CN1763021B (en) | 2010-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1763021B (en) | Method for purifying orlistat | |
CN1824669A (en) | Crystallization method of abamectin Bla | |
CN101041658A (en) | Resolution method for 2-hetero ring substituted dihydropyrimidine racemic compounds | |
KR100582620B1 (en) | Process for the obtaining of HMG-CoA reductase inhibitors of high purity | |
RU2303040C2 (en) | Purification of peptides | |
CN103360411B (en) | Everolimus crystallization and purification method | |
CN104844620A (en) | Separation and purification method for rapamycin | |
CA2640401C (en) | Process for the isolation of calliterpenone (16alpha, 17-dihydroxy-3-oxo-phyllocladane) | |
CN101531629B (en) | Method for preparing levamlodipine from racemic amlodipine maleate | |
CN1290853C (en) | Purifying method for moenomycin | |
RU2260582C2 (en) | Method for purifying pravastatin | |
CN1166634C (en) | 15N-L-proline separating and purifying method | |
CN102321040B (en) | Method for preparing linezolid intermediate and linezolid | |
CN1070843C (en) | Process for crystallization from water of (S)-N,N'-bis[2-hydroxy-1-(hydroxymethyl) ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo-1,3-benzendicarboxamide | |
CN114853593A (en) | Method for extracting high-purity nervonic acid from acer truncatum buge oil | |
EP1670767B2 (en) | Resolution of a narwedine amide derivative | |
CN1286816C (en) | Preparation of liensinine, isoliensinine and methylliensinine extracted from lotus seed | |
CN1226278C (en) | Recovery method of demeclocy cline hydrochloride crystal mother liquor | |
CN1312814A (en) | Improved process for preparing salts and esters of clavulanic acid | |
JP2012506877A (en) | Method for crystallizing erythromycin | |
CN112390715A (en) | Method for extracting shikimic acid and quinic acid from ginkgo leaf extract adsorbed lower column water | |
CN1442407A (en) | Chemical resolution preparation method of optically pure fesufenadin and its hydrochloride salt | |
CN1098265C (en) | Process for refining meloxicam | |
CN114933529B (en) | Method for separating and preparing high-purity ethyl nervonate from acer truncatum kernel | |
CN102993145B (en) | Lovastatin extraction and purification method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: NEW DRUG RESEARCH INSTITUTE CO., LTD. OF HANGZHOU Free format text: FORMER NAME: BIOENGINEERING INST. CO., LTD., HANGZHOU EAST-CHINA MEDICINE GROUP |
|
CP01 | Change in the name or title of a patent holder |
Address after: Hangzhou City, Zhejiang province 310011 Moganshan Road No. 866 Patentee after: HANGZHOU HUADONG MEDICINE GROUP NEW MEDICINE RESEARCH INSTITUTE CO., LTD. Address before: Hangzhou City, Zhejiang province 310011 Moganshan Road No. 866 Patentee before: Hangzhou Huadong Medicine Group Biological Engineering Research Institute Co., Ltd. |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20060426 Assignee: Hangzhou Huadi Pharmaceutical Technology Co.,Ltd. Assignor: Hangzhou Huadong Medicine Group Biopharmaceutical Co.,Ltd. Contract record no.: X2021330000100 Denomination of invention: A method for purifying orlistat Granted publication date: 20100811 License type: Common License Record date: 20210820 |